[ A21-62] Nivolumab (oesophageal cancer) - Addendum to Commission A20-121
Last updated 02.07.2021
Project no.:
A21-62
Commission:
Commission awarded on 11.05.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (after prior fluoropyrimidine- and platinum-based combination chemotherapy)
added benefit not proven.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A20-121 | Nivolumab (oesophageal cancer) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021.07.01 A G-BA decision was published.